Tissue-engineered tregs for the treatment of amyotrophic lateral sclerosis
Active Project Grant Awarded Last action
- Award ID
- HT9425261E077
- Recipient
-
Gentibio, Inc. UEI HNHTFLZ9U5D4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $825,756
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 24% complete
- Place of performance
- Cambridge, MA 02140, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Gentibio, Inc. $825,756 on May 1, 2026, through the Military Medical Research and Development program (CFDA 12.420) to develop tissue-engineered Tregs for the treatment of amyotrophic lateral sclerosis. The award funds basic and applied biomedical research intended to transform health care for Service Members and the American public through innovative medical solutions. Performance runs through June 30, 2028, and takes place in Cambridge, Massachusetts.
Quick answers
Who received award HT9425261E077?
HT9425261E077 was awarded to Gentibio, Inc. by Defense Health Agency (Department of Defense) on May 1, 2026.
How much is award HT9425261E077 worth?
$825,756 has been obligated on HT9425261E077.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award